The thiazolidinediones are a new class of compounds for treatment of type 2 diabetes.
Troglitazone became available in the United States in 1997 but was withdrawn from the …

Troglitazone, the first in the thiazolidinedione class of oral hypoglycaemic agents, was
launched in the USA in March, 1997. It reached Europe later that year, only to be withdrawn …

OBJECTIVE—To determine the efficacy and safety of rosiglitazone (RSG) when added to
insulin in the treatment of type 2 diabetic patients who are inadequately controlled on insulin …

▪ Abstract Type 2 diabetes mellitus is a growing problem not only in the United States but
also across the world. There is now strong evidence that intensive control of blood glucose …

OBJECTIVE—To determine the efficacy of rosiglitazone compared with placebo in reducing
hyperglycemia. RESEARCH DESIGN AND METHODS—After a 4-week placebo run-in …

OBJECTIVES: Previous research has demonstrated that ligands for the γ subtype of
peroxisome proliferator-activated receptors (PPARs) reduce inflammation in two different …

Thiazolidinediones or glitazones specifically target insulin resistance. They have proven
efficacy for reducing plasma glucose levels of type 2 diabetic patients treated with diet alone …

PURPOSE: Cardiovascular complications account for over 50% of mortality among patients
with type 2 diabetes mellitus. We quantify the cardiovascular benefit of lowering cholesterol …

Decreased insulin sensitivity plays a major role in various human diseases, particularly type
2 diabetes mellitus, and is associated with a higher risk of atherosclerosis and …

In this review we present the agents that are in use in the treatment of type 2 diabetes.
Sulfonylureas of the 1 st and 2 nd generation increase insulin secretion but can induce …